Outsourcing Pharma
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
NY Times
DECEMBER 16, 2021
The ruling said the company’s owners, members of the Sackler family, could not receive protection from civil lawsuits in return for a $4.5 billion contribution.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 15, 2021
Words matter. In the pharma industry, “patient engagement” and “patient centricity” might seem like interchangeable bits of corporate jargon. But the difference between them is not like the choice between “agreeing” and “aligning” or “getting together later” and “taking this offline.” Going from the vital activity of patient engagement to the more encompassing state of patient centricity requires big steps in the evolution of new-drug discovery, development, and delivery.
Pharma Times
DECEMBER 9, 2021
In a new report from The Institute of Cancer Research (ICR), data from cancer trials alongside assessments from clinicians and patients aims to provide guidance on how to improve services
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Marketing Network
DECEMBER 17, 2021
The pharma industry has been slower to embrace digital technologies than other less-regulated sectors but the COVID-19 pandemic has greatly changed this long-standing mindset. In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. In this article, R.J. Lewis, Founder & CEO of eHealthcare Solutions and Tap Native, offers his top ten predictions for what’s ahead for pharma in 2022.
Drug Patent Watch
DECEMBER 22, 2021
Annual Drug Patent Expirations for CORLANOR Corlanor is a drug marketed by Amgen Inc and is included in two NDAs. It is available from one supplier. There are eight patents…. The post New patent for Amgen Inc drug CORLANOR appeared first on DrugPatentWatch - Make Better Decisions.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
NY Times
DECEMBER 2, 2021
Spain surpassed others in Europe by avoiding politicized debate about Covid shots. Citizens also largely heeded the health guidance from their leaders.
pharmaphorum
DECEMBER 6, 2021
Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds for the digital health specialist. Pear will make its debut on the exchange today after combining with Thimble Point – a special purpose acquisition company (SPAC) – in a deal that sidestepped the conventional initial public offering (IPO) route and has propelled its valuation to around $1.6 billion.
Pharma Times
DECEMBER 2, 2021
Researchers have identified in those patients experiencing blood clots after vaccination a subsequent condition referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT).
Pharma Marketing Network
DECEMBER 17, 2021
Big pharma has compelling reasons to change the way business gets done. The wave of interest in sustainability follows the value chain from top-tier pharmaceutical companies to their suppliers of every size. Leaders are hard at work focusing their efforts on how to use sustainability as a platform for innovation. Step one is to assess your corporate social responsibility (CSR) policies and ensure actions are integrated across the organization.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
DECEMBER 22, 2021
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
DECEMBER 15, 2021
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
NY Times
DECEMBER 14, 2021
Two drugmakers have been mired for years in the pre-application phase of getting F.D.A. approval for over-the-counter use.
pharmaphorum
DECEMBER 13, 2021
UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor (FcRn) antibody rozanolixizumab for autoimmune disease generalised myasthenia gravis (gMG), setting up regulatory filings next year. The MycarinG study met its primary endpoint, demonstrating a “statistically significant and clinically meaningful” improvement from baseline in the myasthenia gravis-activities of daily living (MG-ADL) score, said the Belgian drugmaker.
Pharma Times
DECEMBER 22, 2021
Calls for booster vaccinations in order to combat the rising cases brought about by winter and the recent Omicron variant have intensified, in the midst of record case rates.
Pharma Marketing Network
DECEMBER 20, 2021
R.J. Lewis, Founder and CEO of eHealthcare Solutions and Tap Native and the Chief Collaborator at Pharma Marketing Network, moderated a deep dive discussion on the topic of physician-level data (PLD) with a focus around drivers for the tool, its usage, and successes learnings about its function in pharma, and the where it’s heading. Guests of the panel included experts from GSK, Ispen, BioPharm Communications, and CMI, who all spoke to the importance of incorporating and leveraging PLD ins
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
DECEMBER 7, 2021
According to a leader from Cytoreason, AI isnât necessarily the best or only tool suited to discover new and novel therapiesâit might take a human touch.
NY Times
DECEMBER 13, 2021
Some laboratory studies suggest that molnupiravir can insert errors in DNA, which could in theory harm a developing fetus, sperm cells or children.
pharmaphorum
DECEMBER 30, 2021
Johnson & Johnson’s much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second candidate. The latest to reach the regulatory stage is teclistamab, one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab.
Pharma Times
DECEMBER 21, 2021
The DETERMINE trial aims to discover whether existing ‘licensed’ drugs could also benefit patients with rare cancer types that the drug is not currently licensed for.
Drug Channels
DECEMBER 13, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. Instead, consider how GoodRx is affecting patients, payers, and PBMs.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for NUPLAZID Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are eighteen…. The post New patent for Acadia Pharms drug NUPLAZID appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
DECEMBER 15, 2021
The Parkinsonâs Progression Markers Initiative, built using Evidation Healthâs research platform, aims to triple enrollment and recruit online participants.
NY Times
DECEMBER 14, 2021
Vuity, a once-a-day treatment that can help users see up close without affecting their long-range vision, went on the market Thursday after being approved by the F.D.A. in October.
pharmaphorum
DECEMBER 21, 2021
Sanofi has bolstered its immuno-oncology pipeline with a $1 billion agreement to acquire Amunix Pharma of the US – its fourth bolt-on deal of 2021. South San Francisco-based Amunix specialises in T-cell engager and cytokine-based treatments for solid tumours, and is planning to advance its lead programme AMX-818 – a cell-based therapy which targets HER2-expressing cancers – into the clinic next year.
Pharma Times
DECEMBER 13, 2021
A team at The Institute of Cancer Research (ICR), London and the Clinical Trials Research Unit (CTRU) at the University of Leeds adopted a new high-speed trial methodology.
Drug Channels
DECEMBER 19, 2021
Happy New Year, everyone! We made it through a challenging 2021. Ring in 2022 with these noisemakers from the Drug Channels party bag: Hospitals earn incredible markups on CAR-T therapies Utilization management booms Health plans often ignore clinical guidelines Benefit designs flummox physicians Plus: an awesomely concise summary of U.S. health insurance.
Drug Patent Watch
DECEMBER 16, 2021
Annual Drug Patent Expirations for XERAVA Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Tetraphase Pharms drug XERAVA appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
DECEMBER 21, 2021
The organization is working to give oncology professionals the chance to hear directly from patients about their unique experiences, concerns, and hopes.
NY Times
DECEMBER 1, 2021
Taken together, the provisions in the social policy bill represent the biggest step toward universal coverage since the passage of the Affordable Care Act.
pharmaphorum
DECEMBER 17, 2021
The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug. The companies had already indicated that the CHMP looked likely to turn down their marketing application for Aduhelm (aducanumab), but the decision nevertheless is a heavy blow, coming as take-up of the drug has pretty much stalled in the US.
Pharma Times
DECEMBER 14, 2021
Nivolumab plus ipilmumab has been accepted as a treatment option for adult patients by NHS Scotland for patients who have previously failed fluoropyrimidine-based chemotherapy.
Drug Channels
DECEMBER 15, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. Charlotte Morabito at CNBC has put together “Why Pharmacies Overcharge,” an entertaining and provocative video on the pharmacy industry and its generic prescription pricing.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for OXTELLAR+XR Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Supernus Pharms drug OXTELLAR XR appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
138 
Let's personalize your content